

Building on the strong basis of INNODIA, with its unique European clinical and fundamental research network for the study of type 1 diabetes (T1D), we propose an ambitious programme that aims to prevent or cure of T1D through objectives that focus on innovation.


Objective of the study

This clinical study with Iscalimab, supplied by Novartis, examines the safety and effectiveness of Iscalimab in children and young adults who have recently been diagnosed with T1D in order to reduce disease progression at the earliest possible time.

Conditions for participation

- Are you aged between 6 and 21?
- Have you been diagnosed with type 1 diabetes in the past 6 weeks?
- Do you weigh between 20 to 30 kg?
- *At this time people with newly diagnosed type 1 diabetes between 6 and 21 years can participate in the study.*
- *However, we are specifically looking for patients who weigh between 20 to 30 kg. Heavier patients were already enrolled in a earlier phase of the study.*

Course of the study



Meal tests week 12, 24, 36 and 52 and month 18, 24 and 36 after the start of the treatment.